{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:00:51Z","timestamp":1781730051307,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.therap.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T18:08:38Z","timestamp":1554401318000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients"],"prefix":"10.1016","volume":"74","author":[{"given":"Biswadeep","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram Singh","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravana Kumar","family":"Ramasubbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.therap.2019.03.008_bib0370","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/01.CIR.0000129322.97266.F3","article-title":"Implantable defibrillators and sudden cardiac death","volume":"109","author":"Josephson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2019.03.008_bib0375","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jelectrocard.2007.06.023","article-title":"Global public health problem of sudden cardiac death","volume":"40","author":"Mehra","year":"2007","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.therap.2019.03.008_bib0380","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.7326\/0003-4819-119-12-199312150-00006","article-title":"Sudden cardiac death: epidemiology, transient risk, and intervention assessment","volume":"119","author":"Myerburg","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2019.03.008_bib0385","doi-asserted-by":"crossref","first-page":"10F","DOI":"10.1016\/S0002-9149(97)00477-3","article-title":"Frequency of sudden cardiac death and profiles of risk","volume":"80","author":"Myerburg","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.therap.2019.03.008_bib0390","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","article-title":"Drug- and non-drug associated QT interval prolongation","volume":"70","author":"van Noord","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.therap.2019.03.008_bib0395","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ihj.2013.11.009","article-title":"Global burden of sudden cardiac death and insights from India","volume":"66","author":"Rao","year":"2014","journal-title":"Indian Heart J"},{"key":"10.1016\/j.therap.2019.03.008_bib0400","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2019.03.008_bib0405","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2019.03.008_bib0410","series-title":"U.S.\u00a0Department of Health and Human Services. Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","year":"2005"},{"key":"10.1016\/j.therap.2019.03.008_bib0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1056-8719(03)00008-X","article-title":"How to correct the QT interval for the effects of heart rate in clinical studies","volume":"48","author":"Davey","year":"2002","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.therap.2019.03.008_bib0420","series-title":"Arizona Center for Education and Research on Therapeutics (AZCERT): QT drug lists by risk groups","year":"2019"},{"key":"10.1016\/j.therap.2019.03.008_bib0425","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.therap.2019.03.008_bib0430","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death","volume":"26","author":"De Bruin","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.therap.2019.03.008_bib0435","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","article-title":"Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death","volume":"26","author":"Straus","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.therap.2019.03.008_bib0440","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcrc.2012.10.014","article-title":"Drug-drug interactions contributing to QT prolongation in cardiac intensive care units","volume":"28","author":"Armahizer","year":"2013","journal-title":"J Crit Care"},{"issue":"13","key":"10.1016\/j.therap.2019.03.008_bib0445","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2019.03.008_bib0450","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"7372","key":"10.1016\/j.therap.2019.03.008_bib0455","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bmj.325.7372.1070","article-title":"Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data","volume":"325","author":"Hennessy","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2019.03.008_bib0460","series-title":"ATC\/DDD Index","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2017"},{"key":"10.1016\/j.therap.2019.03.008_bib0465","series-title":"Medscape drug interaction checker","year":"2018"},{"key":"10.1016\/j.therap.2019.03.008_bib0470","series-title":"Epocrates online interaction check","year":"2019"},{"key":"10.1016\/j.therap.2019.03.008_bib0475","series-title":"Drugs.com. Drug interactions checker","year":"2019"},{"issue":"2","key":"10.1016\/j.therap.2019.03.008_bib0480","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00228-017-2381-5","article-title":"Risk factors for QTc interval prolongation","volume":"74","author":"Heemskerk","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2019.03.008_bib0485","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can Pharm J (Ott)"},{"issue":"6","key":"10.1016\/j.therap.2019.03.008_bib0490","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1540-8159.2008.01085.x","article-title":"Concomitant-acquired long QT and Brugada syndromes associated with indapamide-induced hypokalemia and hyponatremia","volume":"31","author":"Mok","year":"2008","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.therap.2019.03.008_bib0495","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-106-5-712","article-title":"Torsade de pointes and marked QT prolongation in association with hypothyroidism","volume":"106","author":"Kumar","year":"1987","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.therap.2019.03.008_bib0500","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1046\/j.1460-9592.2001.01575.x","article-title":"Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration","volume":"24","author":"Koh","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.therap.2019.03.008_bib0505","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a reversible cause of torsades de pointes in men","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2019.03.008_bib0510","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","article-title":"Influence of steroid hormones on ventricular repolarization","volume":"167","author":"Salem","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"1\u20132","key":"10.1016\/j.therap.2019.03.008_bib0515","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.maturitas.2008.11.011","article-title":"Pharmacological profile of progestins","volume":"61","author":"Sitruk-Ware","year":"2008","journal-title":"Maturitas"},{"issue":"9","key":"10.1016\/j.therap.2019.03.008_bib0520","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamacardio.2018.2251","article-title":"Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women","volume":"3","author":"Salem","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.therap.2019.03.008_bib0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s002280050329","article-title":"Methods for estimating the occurrence of polypharmacy by means of a prescription database","volume":"53","author":"Bjerrum","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0530","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bcp.12969","article-title":"High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Columbia","volume":"82","author":"Moreno-Gutierrez","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.therap.2019.03.008_bib0535","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jsps.2018.07.002","article-title":"Prevalence of torsades de pointes inducing drugs usage among elderly outpatients in North Jordan hospitals","volume":"26","author":"Al-Azayzih","year":"2018","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.therap.2019.03.008_bib0540","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0002-9343(02)01455-9","article-title":"Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients","volume":"114","author":"Curtis","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2019.03.008_bib0545","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11096-014-9953-6","article-title":"Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium","volume":"36","author":"Vandael","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.therap.2019.03.008_bib0550","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s11096-017-0532-5","article-title":"Prevalence of QT-interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicentre cross-sectional study","volume":"39","author":"Khan","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.therap.2019.03.008_bib0555","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.328.7443.794","article-title":"Risk factors, prevalence, and treatment of anxiety and depressive disorders in Pakistan: systematic review","volume":"328","author":"Mirza","year":"2004","journal-title":"Br Med J"},{"key":"10.1016\/j.therap.2019.03.008_bib0560","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4314\/tjpr.v11i2.17","article-title":"Potential drug-drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors","volume":"11","author":"Ismail","year":"2012","journal-title":"Trop J Pharm Res"},{"key":"10.1016\/j.therap.2019.03.008_bib0565","first-page":"3","article-title":"Sociodemographic and clinical characteristics of IV drug users presenting to a tertiary care treatment center","volume":"20","author":"Farooq","year":"2011","journal-title":"J Postgrad Med Inst (Peshawar-Pakistan)"},{"key":"10.1016\/j.therap.2019.03.008_bib0570","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archpsyc.60.7.709","article-title":"Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort","volume":"60","author":"Kim-Cohen","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.therap.2019.03.008_bib0575","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/00004583-199505000-00020","article-title":"Continuity and change of self-reported problem behaviours from adolescence into young adulthood","volume":"34","author":"Ferdinand","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.therap.2019.03.008_bib0580","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14740338.7.2.181","article-title":"Sudden cardiac death secondary to antidepressant and antipsychotic drugs","volume":"7","author":"Sicouri","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.therap.2019.03.008_bib0585","doi-asserted-by":"crossref","first-page":"e0155649","DOI":"10.1371\/journal.pone.0155649","article-title":"Co-prescription of QT-interval prolonging drugs: an analysis in a large cohort of geriatric patients","volume":"11","author":"Schachtele","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.therap.2019.03.008_bib0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-859X-4-1","article-title":"QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy","volume":"4","author":"Sala","year":"2005","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.therap.2019.03.008_bib0595","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1744-859X-6-13","article-title":"QTc and psychopharmacs: are there any differences between monotherapy and polytherapy?","volume":"6","author":"Sumic","year":"2007","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.therap.2019.03.008_bib0600","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.therap.2019.03.008_bib0605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/039463201102400127","article-title":"The use of first-generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTc interval: the Italian experience in a real-world setting","volume":"24","author":"DiSciascio","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0610","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2019.03.008_bib0615","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4088\/JCP.08m04597yel","article-title":"All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study","volume":"70","author":"Liperoti","year":"2009","journal-title":"J Clin Psych"},{"key":"10.1016\/j.therap.2019.03.008_bib0620","doi-asserted-by":"crossref","first-page":"247486","DOI":"10.1155\/2013\/247486","article-title":"Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database","volume":"2013","author":"Murray-Thomas","year":"2013","journal-title":"Cardiovasc Psychiatry Neurol"},{"issue":"4","key":"10.1016\/j.therap.2019.03.008_bib0625","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bcp.12829","article-title":"Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults-A Swedish nationwide study","volume":"81","author":"Danielsson","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0630","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/15622970801910399","article-title":"Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients","volume":"10","author":"Woo","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.therap.2019.03.008_bib0635","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/026988110201600410","article-title":"The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability","volume":"16","author":"Silke","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0640","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.therap.2019.03.008_bib0645","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","article-title":"Severe mental illness and risk of cardiovascular disease","volume":"298","author":"Newcomer","year":"2007","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.therap.2019.03.008_bib0650","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0269881115578162","article-title":"A comparison of risperidone and haloperidol for the risk of ischemic stroke in the elderly: a propensity score-matched cohort analysis","volume":"29","author":"Shin","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0655","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-200302000-00010","article-title":"Psychotropic drugs, cardiac arrhythmia, and sudden death","volume":"23","author":"Witchel","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0660","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2125.2009.03496.x","article-title":"Sudden death in patients receiving drugs tending to prolong the QT interval","volume":"68","author":"Jolly","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0665","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/JCP.0000000000000631","article-title":"Comparative risk of ventricular arrhythmia and sudden cardiac death across antidepressants in patients with depressive disorders","volume":"37","author":"Wu","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2019.03.008_bib0670","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pds.2181","article-title":"Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia","volume":"20","author":"Leonard","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2019.03.008_bib0675","first-page":"687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztbl Int"},{"key":"10.1016\/j.therap.2019.03.008_bib0680","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","article-title":"QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review","volume":"28","author":"Hasnain","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2019.03.008_bib0685","doi-asserted-by":"crossref","first-page":"f288","DOI":"10.1136\/bmj.f288","article-title":"QT interval and antidepressant use: a cross-sectional study of electronic health records","volume":"346","author":"Castro","year":"2013","journal-title":"Br Med J"},{"key":"10.1016\/j.therap.2019.03.008_bib0690","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/PSY.0000000000000054","article-title":"Current perspective on mental stress-induced myocardial ischemia","volume":"76","author":"Krantz","year":"2014","journal-title":"Psychosom Med"},{"key":"10.1016\/j.therap.2019.03.008_bib0695","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1093\/eurheartj\/ehl338","article-title":"Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146538 participants in 54 observational studies","volume":"27","author":"Nicholson","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.therap.2019.03.008_bib0700","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/PSY.0000000000000382","article-title":"Depression and risk of sudden cardiac death and arrhythmias: a meta-analysis","volume":"79","author":"Shi","year":"2017","journal-title":"Psychosom Med"},{"issue":"10","key":"10.1016\/j.therap.2019.03.008_bib0705","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/jat.2784","article-title":"Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment","volume":"32","author":"Wi\u015bniowska","year":"2012","journal-title":"J Appl Toxicol"},{"issue":"4","key":"10.1016\/j.therap.2019.03.008_bib0710","first-page":"121","article-title":"Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports","volume":"1","author":"Vieweg","year":"2013","journal-title":"Ther Adv Infect Dis"},{"issue":"11","key":"10.1016\/j.therap.2019.03.008_bib0715","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1586\/14779072.2013.840535","article-title":"Torsades de pointes following clarithromycin treatment","volume":"11","author":"Gysel","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.therap.2019.03.008_bib0720","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/clpt.2011.150","article-title":"Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software","volume":"90","author":"Haueis","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2019.03.008_bib0725","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"Gupta","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.therap.2019.03.008_bib0730","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40266-014-0188-y","article-title":"Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study","volume":"31","author":"Goutelle","year":"2014","journal-title":"Drugs Aging"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:52:48Z","timestamp":1758567168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719300642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0040595719300642"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.03.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}